nice one. unfortunately the ASX no longer allow biotechs to include comparisons in trial data announcements. If they did, it's highly likely BOT would have included that Mupirocin has a current known efficacy of about 60%, and some hospitals are seeing resistance levels of more than 90% to that treatment. Hoping they are allowed to include this in their next investor presentation.
nice one. unfortunately the ASX no longer allow biotechs to...
-
- There are more pages in this discussion • 60 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
36.0¢ |
Change
-0.010(2.70%) |
Mkt cap ! $651.6M | |||
| Open | High | Low | Value | Volume |
| 37.0¢ | 37.0¢ | 35.5¢ | $1.395M | 3.870M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 50000 | 35.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 36.0¢ | 266249 | 5 |
View Market Depth
| Last trade - 16.10pm 19/08/2024 (20 minute delay) ? |
| BOT (ASX) Chart |